Physician profile
Eric W Perttula
NPI 1710988894
$2,809.63
in general payments reported to CMS, 2019-2025
26 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $363 · 2021: $305 · 2022: $455 · 2023: $429 · 2024: $462 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $627.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $371.35 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $340.62 | 2021-2025 | |
| Novo Nordisk INC | $339.17 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.19 | 2019-2023 | Synjardy, Jardiance |
| Amgen INC. | $157.13 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $107.76 | 2019-2022 | |
| Glaxosmithkline, LLC. | $105.64 | 2019-2023 | Shingrix, Bexsero, Arexvy |
| Boston Scientific Corporation | $67.66 | 2022-2025 | General - Pain Management |
| Allergan, INC. | $66.00 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $52.01 | 2019 | |
| Amarin Pharma, INC. | $51.65 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $50.79 | 2019-2021 | |
| Pfizer INC. | $44.47 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $31.47 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.78 | 2020 | |
| Astellas Pharma US INC | $28.06 | 2023 | Veozah |
| Abbott Laboratories | $23.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.40 | 2024 | Spravato |
| Antares Pharma, INC. | $16.96 | 2019 | |
| Sirtex Medical INC | $16.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.23 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.85 | 2025 | Caplyta |
| Celgene Corporation | $15.25 | 2022 | |
| Shire North American Group INC | $15.07 | 2019 | |
| Eisai INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Perttula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.